[Ip-health] EU roadmap for TTIP

Meri Koivusalo merikoivusalo at yahoo.co.uk
Wed Mar 20 07:47:02 PDT 2013

There are links also to this  impact assessment which is on the website, which has special section on pharmaceutical policies, where it would be good to know how the impact on welfare gains have actually been calculated and for whom as it is unclear
if it really implies that welfare gains are for US pharmaceutical exporters for EU government procurement would pay more for medicines,...: 

The pharmaceuticals sector is important for both the EU and US economies, and transatlantic trade is affected by several important regulatory divergences leading to NTMs for this sector; 
The most important issues for US companies exporting to the EU – constituting the estimated trade  costs  of  15.3  percent  –  relate  in  particular  to  EU  pricing  policies,  the  EU  Health Technology   Assessment   methods,   divergent   national   authorisation systems   (although decreasing  in  importance),  data  exclusivity,  parallel  trading,  international  and  therapeutic reference pricing and customs administration differences and delays; 
For  EU  firms,  the  potential  trade  cost  reductions  of  9.5  percent  in  pharmaceuticals  when exporting  to  the  US  are  associated  with  the  removal  of  restrictions  on  specific  chemicals, labelling  requirements,  re-exporting  licences,  US  state  le
vel  safety  regulations,  double-certification needs (like above for US firms), and differences with US patent legislation; 
Many of the measures in the sector have high potential to be reduced. For example, in the EU High-level Pharmaceutical Forum, work has already started on addressing some issues. Also, in the Transatlantic Economic Council, US and EU authorities have increased cooperation on addressing some of these issues; 

Total,  actionable  welfare  gains  of  reducing  NTMs  amoun t  to € 2.2  billion  ($2.9  billion)  per year; Most of the NTMs in the sector will directly affect the market structure, efficiency and costs of  producers.  For  example,  the  possible  end  to  discrimination 
of  non-US  producers  in  US R&D support (Technology Innovation Programme) and in public procurement could create a more level playing field. 

 From: Thirukumaran Balasubramaniam <thiru at keionline.org>
To: a2k at lists.keionline.org; Ip-health at lists.keionline.org 
Sent: Wednesday, 20 March 2013, 12:01
Subject: [Ip-health] EU roadmap for TTIP


Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International (KEI)

thiru at keionline.org

Tel: +41 22 791 6727
Mobile: +41 76 508 0997

Ip-health mailing list
Ip-health at lists.keionline.org

More information about the Ip-health mailing list